The CHA2DS2-VASc score well stratifies the risk for thromboembolic events in non-valvular atrial fibrillation (NVAF) patients. This score may also predict thromboembolic events in sinus rhythm populations.
Purpose
The purpose of this study was to assess the prognostic role of CHA2DS2-VASc in a Caucasian community population of patients with arterial hypertension and sinus rhythm.
Methods
A total of 12,599 arterial hypertension residents not receiving anticoagulation were selected from a community population in Trieste between November 2009 and October 2014: 11,159 sinus rhythm and 1440 NVAF patients. We considered thromboembolic events, cardiovascular hospitalisation and all-cause death in all patients divided according to CHA2DS2-VASc.
Results
Sinus rhythm patients were 74 (interquartile range 65–81) years old, 50% were women, 32% with CAD, mean CHA2DS2-VASc 3.68 ± 1.47 points, significantly lower than NVAF patients (4.26 ± 1.50, P < 0.001). After 37 months follow-up, an increasing CHA2DS2-VASc corresponded to a higher rate of thromboembolic events in sinus rhythm patients, ranging from 0% in patients with a score of 1 or 2 to 2.6% in those with a score of 6 or greater (P < 0.0001). A similar trend was found in the reference NVAF group. At Cox multivariable analysis, CHA2DS2-VASc predicted thromboembolic events (hazard ratio (HR) 2.12), cardiovascular hospitalisation (HR 1.55) and all-cause death (HR 1.57). The predictive accuracy of CHA2DS2-VASc was similar in sinus rhythm and NVAF patients for thromboembolic events, cardiovascular hospitalisation and all-cause death (area under the curve statistic 0.76 vs. 0.76, 0.68 vs. 0.66, 0.64 vs. 0.64, respectively).
Conclusions
In a community population of Caucasian arterial hypertension patients in sinus rhythm, CHA2DS2-VASc rather well stratifies for adverse clinical events at mid-term follow-up with a similar accuracy to NVAF patients. These results might be clinically relevant in this setting of sinus rhythm patients.
Authors/Task Force MembersPiepoliMFHoesAWAgewallSet al.2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur J Prev Cardiol2016; 23: NP1–N96.
2.
LaslettLJAlagonaPClarkBAet al.The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol2012; 25: S1–S49.
3.
KearneyPM1WheltonMReynoldsKet al.Worldwide prevalence of hypertension: a systematic review. J Hypertens2004; 22: 11–19.
4.
WuSChiHJinCet al.The association of blood pressure with survival rate and cardiovascular events in Chinese patients with type 2 diabetes. Int J Cardiol2013; 168: 4514–4515.
5.
LawesCMVander HoornSRodgersA. International Society of Hypertension Global burden of blood-pressure-related disease, 2001. Lancet2008; 371: 1513–1518.
6.
GorguiJGorshkovMKhanNet al.Hypertension as a risk factor for ischemic stroke in women. Can J Cardiol2014; 30: 774–782.
7.
CammAJLipGYDe CaterinaRet al.2012 Focused update of the ESC guidelines for the management of atrial fibrillation. An update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J2012; 33: 2719–2747.
8.
JanuaryCTWannLSAlpertJSet al.2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol2014; 64: 2246–2280.
9.
YouJJSingerDEHowardPAet al.Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest2012; 141: e531S–e575S.
10.
LipGYNieuwlaatRPistersRet al.Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart survey on atrial fibrillation. Chest2010; 137: 263–272.
11.
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2016; 37: 2893–2962.
12.
RogerVLGoASLloyd-JonesDMet al.Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation2011; 123: e18–e209.
13.
MitchellLBSouthernDAGalbraithD1et al.APPROACH investigators. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart2014; 100: 1524–1530.
14.
LipGY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?Eur Heart J2013; 34: 1041–1049.
15.
MelgaardLGorst-RasmussenALaneDAet al.Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA2015; 314: 1030–1038.
16.
WolskELambertsMHansenMLet al.Thromboembolic risk stratification of patients hospitalised with heart failure in sinus rhythm: a nationwide cohort study. Eur J Heart Fail2015; 17: 828–836.
17.
PoçiDHartfordMKarlssonTet al.Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest2012; 141: 1431–1440.
18.
WellesCCWhooleyMANaBet al.The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the Heart and Soul Study. Am Heart J2011; 162: 555–561.
19.
PodoleckiTLenarczykRKowalczykJet al.Stroke and death prediction with CHA2DS2-VASc score after myocardial infarction in patients without atrial fibrillation. J Cardiovasc Med2015; 16: 497–502.
20.
MorillasPPallarésVFácilaLet al.FAPRES registry investigators. The CHADS2 score to predict stroke risk in the absence of atrial fibrillation in hypertensive patients aged 65 years or older. Rev Esp Cardiol2015; 68: 485–491.
21.
De CaterinaRCammAJ. What is ‘valvular’ atrial fibrillation?A reappraisal. Eur Heart J2014; 14: 3328–3335.
22.
LipGYHNieuwlaatRPistersRet al.Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest2010; 137: 263–272.
23.
BlanchePDartiguesJFJacqmin-GaddaH. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med2013; 32: 5381–5397.
24.
GlotzerTVHellkampASLeeKLet al.CHA2DS2-VAS(C) and CHADS2 scores predict adverse clinical events in patients with pacemakers and sinus node dysfunction independent of atrial fibrillation. Can J Cardiol2015; 31: 1004–1011.
25.
LipGYLinHJChienKLet al.Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. Int J Cardiol2013; 168: 414–419.
26.
WolfPAAbbottRDKannelWB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke1991; 22: 983–988.
TuHTHCampbellBCVMeretojaAet al.VISTA collaborators: pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation. Cerebrovasc Dis2013; 36: 273–280.
29.
LacklandDTRoccellaEJDeutschAFet al.American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Council on Functional Genomics and Translational Biology. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke2014; 45: 315–353.
30.
GotoSBhattDLRötherJet al.REACH Registry Investigators. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J2008; 156: 855–863.
31.
OhiraTShaharEChamblessLet al.Risk factors for ischemic stroke subtypes. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke2006; 37: 2493–2498.
32.
Chong AY, Freestone B, Lim HS, et al. Plasma von Willebrand factor and soluble E-selectin levels in stable outpatients with systolic heart failure: the Frederiksberg Heart Failure Study. Int J Cardiol 119; 1: 80–82.
33.
DriesDLRosenbergYDWaclawiwMAet al.Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol1997; 29: 1074–1080.
34.
McClungJANaseerNSaleemMet al.Circulating endothelial cells are elevated in patients with type 2 diabetes mellitus independently of HbA(1)c. Diabetologia2005; 48: 345–350.
35.
Akoum N. New perspectives on atrial fibrillation and stroke. Review. Heart 2016; 102: 1788–1792.
36.
WallmannDTüllerDWustmannKet al.EMBRACE Steering Committee and Investigators. Frequent atrial premature beats predict paroxysmal atrial fibrillation in stroke patients: an opportunity for a new diagnostic strategy. Stroke2007; 38: 2292–2294.
37.
GladstoneDJDorianPSpringMet al.EMBRACE Steering Committee and Investigators. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. Stroke2015; 46: 936–941.
